CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.
Paula Rodriguez-MarquezMaria Eréndira Calleja-CervantesGuillermo SerranoMarta GarroteMaria L Palacios-BerraqueroAngel Martin-MalloCristina Calviño-SampedroMarta Español-RegoCandela CeballosTeresa LozanoPatxi San Martin-UrizAmaia Vilas-ZornozaSaray Rodriguez-DiazRebeca Martinez-TurrillasPatricia JaureguiDiego AlignaniMaría Cruz ViguriaMargarita RedondoMariona PascalBeatriz Martin-AntonioManel JuanAlvaro Urbano-IspizuaPaula Rodriguez OteroAna AlfonsoJuan José LahuertaJuan Jose LasarteSusana InogesAscensión López-Díaz de CerioJesús San F MiguelCarlos Fernández de LarreaMikel HernaezJuan Roberto Rodriguez-MadozFelipe ProsperPublished in: Science advances (2022)
Identification of new markers associated with long-term efficacy in patients treated with CAR T cells is a current medical need, particularly in diseases such as multiple myeloma. In this study, we address the impact of CAR density on the functionality of BCMA CAR T cells. Functional and transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct show an increased tonic signaling with up-regulation of exhaustion markers and increased in vitro cytotoxicity but a decrease in in vivo BM infiltration. Characterization of gene regulatory networks using scRNA-seq identified regulons associated to activation and exhaustion up-regulated in CAR High T cells, providing mechanistic insights behind differential functionality of these cells. Last, we demonstrate that patients treated with CAR T cell products enriched in CAR High T cells show a significantly worse clinical response in several hematological malignancies. In summary, our work demonstrates that CAR density plays an important role in CAR T activity with notable impact on clinical response.